A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
about
Understanding the interplay between host immunity and Epstein-Barr virus in NPC patientsEpstein-barr virus vaccines.Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma.Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored VaccinesTherapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.Cytotoxic CD4 T Cells-Friend or Foe during Viral Infection?Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.Immunotherapy against cancer-related viruses.A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in miceEpstein-Barr virus: more than 50 years old and still providing surprises.Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus.Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.Therapeutic cancer vaccines.Current Strategies to Enhance Anti-Tumour Immunity.Targeting Head and Neck Cancer by Vaccination.Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines.Epstein-Barr virus and nasopharyngeal carcinomaRole of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target
P2860
Q26823898-7AB7FC08-0F94-427F-8BDE-9776BBF19A4DQ35053650-B218F394-6406-482D-955B-FFD8166B28F9Q35832185-C9A76C05-96A1-4786-B72D-3A835DD37D99Q35928588-0AF198A8-A9D6-4820-AEB8-24721E1B2C17Q36241068-B48C60D6-6408-4ED4-A9B0-E91161761B24Q37597931-9225E689-C335-4CEA-9608-989130AAA21DQ37745980-32A21BF7-7BB8-4AE1-B4B0-7D2A505E6E50Q38635035-8225FF21-887A-4DF3-BB61-98CBB71E99C8Q38778924-3D65D21F-A0D0-4D50-90F2-EDE4E260D973Q38885776-78DD6FFE-DAC5-43CF-913E-848A61312AB1Q38968588-CCF7BBA0-E1B2-4982-8DFA-6400A680B479Q39170011-7DF2B23D-A4F1-44D1-B446-5B1103C40C9AQ40967391-43DA3625-AD03-47D2-88D0-F05240625045Q49787173-BE8997E9-9FAE-4252-9F05-2A1B97670E46Q50988785-FE8CFBEF-86E8-4AED-BA90-2C511D588B45Q52344613-73BDFC9A-04F0-4629-9EA9-EFB3527474E6Q54217605-4C8B5032-7FC7-4B53-AE94-6471AD585B2BQ54249887-FBD10D00-7430-42FD-AA81-CF6B94D88288Q56947843-2C877797-8622-49B1-AD93-8EBA0C5D0C12Q57176933-06244D3F-ED9D-4B75-BC9D-9ACE191392A8
P2860
A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A recombinant modified vaccini ...... ents with EBV-positive cancer.
@ast
A recombinant modified vaccini ...... ents with EBV-positive cancer.
@en
type
label
A recombinant modified vaccini ...... ents with EBV-positive cancer.
@ast
A recombinant modified vaccini ...... ents with EBV-positive cancer.
@en
prefLabel
A recombinant modified vaccini ...... ents with EBV-positive cancer.
@ast
A recombinant modified vaccini ...... ents with EBV-positive cancer.
@en
P2093
P2860
P50
P1476
A recombinant modified vaccini ...... ents with EBV-positive cancer.
@en
P2093
Alan B Rickinson
Ceri Edwards
Claudia Roberts
Edwin P Hui
Graham S Taylor
Jen Matthews
Kevin Harrington
Lesley McGuigan
Lip Wai Lee
P2860
P304
P356
10.1158/1078-0432.CCR-14-1122-T
P407
P577
2014-08-14T00:00:00Z